


## PF-04979064

<b>Cat. No.:</b>	HY-100398		
<b>CAS No.:</b>	1220699-06-8		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	446.5		
<b>Target:</b>	PI3K; mTOR		
<b>Pathway:</b>	PI3K/Akt/mTOR		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 10 mg/mL (22.40 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.2396 mL	11.1982 mL	22.3964 mL
		5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM		0.2240 mL	1.1198 mL	2.2396 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 1 mg/mL (2.24 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (2.24 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 1 mg/mL (2.24 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with K <sub>i</sub> s of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.			
<b>IC<sub>50</sub> &amp; Target</b>	PI3Kα 0.13 nM (K <sub>i</sub> )	PI3Kγ 0.111 nM (K <sub>i</sub> )	PI3Kδ 0.122 nM (K <sub>i</sub> )	mTOR 1.42 nM (K <sub>i</sub> )
<b>In Vitro</b>	PF-04979064 is tested against human class I PI3K isoforms PI3Kα, PI3Kγ, and PI3Kδ, with PI3Kα K <sub>i</sub> of 0.13 nM, PI3Kγ K <sub>i</sub> of			

---

0.111 nM, and PI3K $\delta$  K<sub>i</sub> of 0.122 nM<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

PF-04979064 is progressed to rat in vivo PK studies and exhibits robust PK profile: Vd<sub>ss</sub>=5.23 L/kg, Cl=19.3 mL/min/kg, T<sub>1/2</sub>=1.85 h, and F%=61%<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Mol Immunol. 26 December 2021.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

[1]. Cheng H et al. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett, 2012 Nov 7, 4(1):91-7.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA